Evidence map›Paper›PMID 38093288›Full record

ArticleMolecular cancer2023

Hsa_circ_0136666 stimulates gastric cancer progression and tumor immune escape by regulating the miR-375/PRKDC Axis and PD-L1 phosphorylation.

Zhenyan Miao, Jifei Li, Yu Wang, Mingqin Shi, Xiao Gu, Xuanqi Zhang, Fang Wei, Xinying Tang, Lufeng Zheng, Yingying Xing

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 1 pooled it
14.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. NAT10-Mediated ac4C Modification of circANKRD12 Reprograms the Tumor Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Role of histone modifications in gastric cancer (Review).International journal of oncology · 2026
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Zhenyan Miao *School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Jifei Li *School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Yu WangState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Mingqin ShiSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Xiao GuSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Xuanqi ZhangSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Fang WeiSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Xinying TangState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. xinyingtang@cpu.edu.cn.
Lufeng ZhengSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. zhlf@cpu.edu.cn.
Yingying XingSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. cpuskyxyy@126.com.
China Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTargeted drugs are not quite effective for prolonging the survival of patients with gastric cancer due to off-target effects as well as tumor immune escape mechanisms. Circular RNAs widely exist in tumor regions as biomarkers and can be developed as effective drug targets.

methodsWestern blot, QRT-PCR, fluorescence in situ hybridization, and flow cytometry were used to investigate the function of hsa_circ_0136666 in promoting the proliferation of gastric cancer cells. Tissue immunofluorescence, enzyme-linked immunosorbent assay (ELISA), as well as flow cytometric analysis, was conducted to explore the process of tumor immune evasion in tumor-bearing mice. The differences of circRNA expression in clinical samples were analyzed through tissue microarray FISH. The effect of siRNA on improving the efficacy of anti-PDL1 drugs and suppressing the immune microenvironment was evaluated by the coadministration model.

resultsWe demonstrated that hsa_circ_0136666 was widely and highly expressed in gastric cancer tissues and cells. Functionally, hsa_circ_0136666 promoted gastric cancer tumor proliferation and tumor microenvironment formation, leading to tumorigenesis immune escape, and this effect was dependent on CD8 + T cells. Mechanistically, we confirmed that hsa_circ_0136666 competitively upregulated PRKDC expression by sponging miR-375-3p, regulating immune checkpoint proteins, prompting phosphorylation of PD-L1 to preventing its degradation, driving PD-L1 aggregation and suppressing immune function, thereby impairing cancer immune responses. In terms of application, we found that LNP-siRNA effectively improved anti-PDL1 drug efficacy and inhibited immune escape.

conclusionOur results reveal an oncogenic role played by hsa_circ_0136666 in gastric cancer, driving PD-L1 phosphorylation via the miR-375/PRKDC signaling axis, prompting immune escape. This work proposes a completely new pathogenic mechanism of gastric cancer, uncovers a novel role for hsa_circ_0136666 as an immune target, and provides a rationale for enhancing the efficacy of anti-PD-L1 therapy for gastric cancer.

Indexed as

MicroRNAsStomach NeoplasmsAnimalsB7-H1 AntigenCell Line, TumorCell ProliferationDNA-Activated Protein KinaseHumansIn Situ Hybridization, FluorescenceMicePhosphorylationRNA, Small InterferingTumor EscapeTumor MicroenvironmentB7-H1 AntigenDNA-Activated Protein KinaseMicroRNAsMIRN375 microRNA, humanPRKDC protein, humanRNA, Small InterferingCircular RNAGastric cancerImmune escapemiR-375PD-L1

Identifiers

PMID38093288
PMCPMC10718020
OpenAlexW4389682458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.